Xixin Yan 1 , Yuanlin Song 2 , 3 , Ce Shen 4 , Wenbing Xu 5 , Liangan Chen 6 , Jian Zhang 7 , Huiguo Liu 8 , Mao Huang 9 , Guoxiang Lai 10 , Guishen Qian 11 , Jing Wang 12 , Xianwei Ye 13 , Jinping Zheng 14 , Chunxue Bai 2
22 March 2017
Airway mucus hypersecretion is a frequent symptom associated with acute and chronic airway disease. Inhibition of mucus production or promotion of mucolysis not only relieved symptoms but also improved disease outcomes. There are numerous available mucoactive medicines for prescription, and how to select them properly for different diseases is important for clinical practice. So far, there is no one consensus or guideline reported. A group of Chinese pulmonary physicians worked together to complete this consensus based on literature review, summarized mechanism and usage of each classical mucoactive medicine. In general, antioxidant mucoactive medicines play an important role in chronic airway disease, including but not limited to airway mucus clearance, reduced acute exacerbation and improved pulmonary function.